Clinical Trials Logo

Idiopathic Pulmonary Fibrosis clinical trials

View clinical trials related to Idiopathic Pulmonary Fibrosis.

Filter by:

NCT ID: NCT02885961 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

The Coagulation Cascade in Idiopathic Pulmonary Fibrosis

Start date: August 2016
Phase: N/A
Study type: Interventional

The pathogenesis of idiopathic pulmonary fibrosis (IPF) is incompletely understood but recurrent epithelial injury occurs which evokes the coagulation cascade. Thrombin is produced as a result and is over expressed in IPF patients, so may be important in propagating disease activity. We aim to recruit patients with IPF and then complete FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET (positron emission tomography) scans pre and post manipulation of the coagulation cascade to assess the role of this biological pathway in disease activity. Previous studies from our institution have demonstrated increased FDG avidity in the lungs of patients with IPF (assessed using FDG PET scans) but to date the cells and pathways responsible for this signal have not been identified and thus need further exploration.

NCT ID: NCT02874989 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis (IPF)

Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial

IPF
Start date: August 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether dasatinib and quercetin can reduce the expression of pro-inflammatory cells obtained by skin biopsy.

NCT ID: NCT02871401 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)

Start date: September 2016
Phase: Phase 1
Study type: Interventional

The investigators will conduct a single-center, prospective, randomized, placebo-controlled, double-blind pilot study of anti-herpesvirus therapy in patients with idiopathic pulmonary fibrosis (IPF). Patients with mild, moderate or severe IPF with serologic evidence of current or past Epstein-Barr Virus (EBV) or cytomegalovirus (CMV) infection. Randomization will be to pirfenidone plus placebo or pirfenidone plus valganciclovir. Thirty subjects will be enrolled and randomized to treatment with pirfenidone plus valganciclovir (20 subjects) or pirfenidone plus placebo (10 subjects) for 12 weeks. The primary outcome will be safety and tolerability will be determined by type, frequency and duration of adverse events (AEs) and serious adverse events (SAEs) after 12 weeks of study drug treatment. All study subjects will be offered bronchoscopy with bronchoalveolar lavage (BAL) at study initiation and upon completion of treatment (12 weeks). Subjects will then be followed up at routine clinic visits at 6, 9 and 12 months for data collection.

NCT ID: NCT02848625 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Yoga Effect on Quality of Life Study Among Patients With Idiopathic Pulmonary Fibrosis

YES-IPF
Start date: August 2016
Phase: N/A
Study type: Interventional

This study will evaluate whether regular yoga exercises designed specifically for patients with Idiopathic Pulmonary Fibrosis is associated with any change in quality of life. Half of the participants will be randomized to yoga, half to usual care. After the first group completes 12 weeks of yoga, the patients who were randomized to usual care will completed 12 weeks of yoga.

NCT ID: NCT02846324 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

Start date: June 2016
Phase: Phase 2
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.

NCT ID: NCT02827734 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)

Start date: October 2015
Phase: N/A
Study type: Observational

Current diagnostic tools used in interstitial lung disease (ILD) do not meet the challenges set by the complex pathophysiology of this heterogenous group. The investigators therefore aimed to evaluate novel or not widely used diagnostic approaches for the detection and therapeutic monitoring of patients with various ILDs.

NCT ID: NCT02821039 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Turkish Thoracic Society Usual Interstitial Pneumonia Registry Study

TURK-UIP
Start date: June 2016
Phase: N/A
Study type: Observational [Patient Registry]

The Turkish Thoracic Society Usual Interstitial Pneumonia Registry (TURK-UIP) is a collaborative project to coordinate a team of investigators from various regions of Turkey. The purpose of the Registry is to collect epidemiological data on patients with idiopathic pulmonary fibrosis and other causes of UIP, and to obtain information about the natural course of the disease and the treatment response.

NCT ID: NCT02818712 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nationwide Follow-up

Start date: August 2016
Phase: N/A
Study type: Observational

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a high mortality. Health-related quality of life (HRQL) is impaired in patients with IPF. Little is known about the properties of recently developed HRQL questionnaires and about the longitudinal changes in HRQL, including factors with an impact on HRQL. Comorbidities have an impact on patients with IPF, but reports differ in incidence and prevalence. The impact of comorbidities on HRQL and disease progression has only been studied sparsely. Also, the association between biomarkers and disease progression need to be examined further.

NCT ID: NCT02803580 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis

Start date: November 2015
Phase: N/A
Study type: Observational

The purpose of the present study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise tolerance during 12 months of observation.

NCT ID: NCT02802345 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

Start date: June 2016
Phase: Phase 3
Study type: Interventional

Efficacy will be assessed by the change from baseline in St George's Respiratory Questionnaire (SGRQ) total score at week 12 and at week 24; by the change from baseline in dyspnea using the University of California San Diego Shortness of Breath Questionnaire (UCSC SOBQ) at week 12 and at week 24; whereas safety will be assessed by the percentage of patients with on-treatment Serious Adverse Events (SAE) from baseline to week 24.